MuReva Phototherapy presented data from a pilot prospective  study of the company’s Intraoral Photobiomodulation (PBM) Device during the the American Society for Radiation Oncology’s (ASTRO) 65th Annual Meeting held from October 1-4, 2023 in San Diego, California. The company reported results associated with the use of the PBM device in 36 patients at 7 sites with head and neck cancer being undergoing Intensity-modulated radiation therapy (IMRT).

The results from the pilot study were encouraging with a reduction in the severity of oral mucositis and for the the retention of salivary flow and swallowing ability. Treatment with the PBM device was well tolerated (97% of treatments were completed in full), safe with no device-related adverse events and 97% of subjects being satisfied with their treatment experience.

Click on the image below to enlarge.